NCT00382187View on ClinicalTrials.gov

Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Influenza
Interventions
BIOLOGICAL

MF59 adjuvanted H5N1 influenza vaccine

"* MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1~* non-adjuvanted influenza vaccine containing 15 ug of H5N1"

Trial Locations (1)

53100

Presidio Distrettuale N. 8, Azienda USL 7 di Siena, Via Savina Petrilli, 3, Siena

Sponsors

Lead Sponsor

Novartis Vaccines
All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY